Loading...
 
Back to the list
Mediterr J Rheumatol 2022;33(1):42-7
Article Links
Rheumatoid Arthritis Co-relation with Anti-CCP Antibodies with special reference to its Prevalence in Asymptomatic First-Degree Relatives
Pramod GR1, Prasanta Dihingia2, Anshu Kumar Jha3, Akash Gadgade4, Deepti Agarwal5
Authors Information

1Department of Nephrology, S.S. Institute of Medical Sciences, Davangere, Karnataka, India

2Department of Medicine, Assam Medical College and Hospital, Dibrugarh, Assam, India

3Department of Cardiology, Assam Medical College and Hospital, Dibrugarh, Assam, India

4Senior Manager, Medical and Scientific Affairs, Navitas Life Sciences, Bengaluru

5Department of Medicine, S.S. Institute of Medical Sciences, Davangere, Karnataka, India

Keywords: rheumatoid arthritis, asymptomatic first-degree relative, anti-cyclic citrullinated peptide antibody
References
  1. Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum 2006;36(3):182-8.
  2. Carmona L, Gonzalez-AI, Balsa A, Angel Belmonte M, Tena X, Sanmartí R. Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. Ann Rheum Dis 2003;62:897-900.
  3. Young A, Koduri G. Extra-articular manifestations and complications of rheumatoid arthritis. Best Pract Res ClinRheumatol 2007;21(5):907-927.
  4. Kolfenbach JR, Deane KD, Derber LA, O'Donnell C, Weisman MH, Buckner JH, et al. A pro­spective approach to investigating the natural history of preclinical rheumatoid arthritis (RA) using first-degree relatives of probands with RA. Arthritis Rheum 2009;61:1735-1742.
  5. Hazelton RA, Cross SM, Robert G, Strachan N. A family study of the prevalence of antibodies to the rheumatoid arthritis associated nuclear antigen (RANA). Br J Rheu­matol 1986;25:349-352.
  6. Serdaroglu M, Çakırbay H, Deger O, Cengiz S, Kul S. Rheumatol Int 2008 August; 28(10):965-970.
  7. Arlestig L, Mullazehi M, Kokkonen H, Rocklov J, Ron­nelid J, Dahlqvist SR. Antibodies against cyclic citrul­linated peptides of IgG, IgA and IgM isotype and rheumatoid factor of IgM and IgA isotype are increased in unaffected members of multicase rheumatoid arthri­tis families from northern Sweden. Ann Rheum Dis 2012;71:825-829.
  8. Jirholt J, Lindqvist AB, Holmdahl R. The genetics of rheumatoid arthritis and the need for animal models to find and understand the underlying genes. Arthritis Res Ther 2001;3:87.
  9. Chou C, Liao H, Chen Ch, Chen W, Wang H, Su K. The clinical application of anti-CCP in rheumatoid arthritis and other rheumatic diseases. Biomark Insights 2007;2:165-71.
  10. Kobak S, Bes C. An autumn tale: geriatric rheumatoid arthritis. Ther Adv Musculoskelet Dis 2018;10:3-11.
  11. Shankar S, Grover R, Handa R. Role of anti cycliccitrullinated peptide antibodies in erosive disease in patients with rheumatoid arthritis. Indian J Med Res 2006;124:689-96.
  12. Gabriel SE, Crowson CS, O'Fallon M. The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955-1985. Arthritis Rheum 1999;42:415-20.
  13. Fatima N, Shameem M, Malik A, Khan PA, Shujatullah F, et al. A Study on the Pulmonary Manifestations of Rheumatoid Arthritis from a North Indian Town. Open J Respir Dis 2013;3:128-31.
  14. Aletaha D, Ward MM. Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials. Ann Rheum Dis 2006;65:227-33.
  15. Cader MZ, Filer AD, Buckley CD, Raza K. The relationship between the presence of anti-cyclic citrullinated peptide antibodies and clinical phenotype in very early rheumatoid arthritis. BMC Musculoskelet Disord 2010;11:187
  16. Kim HH, Kim J, Park SH, Kim SK, Kim OD, Choe JY. Correlation of anti-cyclic citrullinated antibody with hand joint erosion score in rheumatoid arthritis patients. Korean J Intern Med 2010;25(2):201-06.
  17. Klareskog L, Widhe M, Hermansson M, Rönnelid J. Antibodies to citrullinated proteins in arthritis: pathology and promise. Curr Opin Rheumatol 2008 May;20(3):300-5.
  18. Chen J, Shi Y, Wang X, Huang H, Ascherman D. Asymptomatic Preclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease. Clin Dev Immunol 2013;2013:Article ID 406927.
  19. Biomdo I, Omondi GO, Mecha J, Chakaya M. Assessment of pulmonary function in rheumatoid arthritis patients attending Rheumatology Clinics in Nairobi. Afr J Rheumatol 2013;1(2):39-44.
  20. Mansoor K, Mansour S, Ziba F. The association of Anti-CCP1 antibodies with disease activity score 28 (DAS‑28) in rheumatoid arthritis. Adv Biomed Res 2012;1(2):1-4.
  21. Yadollah S, Susan K, Ahmad RJ, Ali AA, Ahmad M, Amir K, et al. Anti-Cyclic Citrullinated Peptide Antibody and Rheumatoid Factor Isotypes in Iranian Patients with Rheumatoid Arthritis: Evaluation of Clinical Value and Association with Disease Activity. Iran J Allergy Asthma Immunol 2014;13(3):147-156.
  22. Lee DM, Schur PH. Clinical utility of the Anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 2003;62:870-4.
  23. del Val del Amo N, Ibanez Bosch R, Fito Manteca C, Gutierrez Polo R, Loza Cortina E. Anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: Relation with disease aggressiveness. Clin Exp Rheumatol 2006;24(3):281-6.
  24. Panagopoulos PK, Lambrou GI. Bone erosions in rheumatoid arthritis: recent developments in pathogenesis and therapeutic implications. J Musculoskelet Neuronal Interact 2018;18(3):304-19.
  25. Greiner A, Plischke H, Kellner H, Gruber R. Association of anti‑cyclic citrullinated peptide antibodies, anti‑citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis. Ann N Y Acad Sci 2005;1050:295‑303.
  26. Richman NC, Yazdany J, Graf J, Chernitskiy V, Imboden JB. Extraarticular manifestations of rheumatoid arthritis in a multiethnic cohort of predominantly Hispanic and Asian patients. Medicine (Baltimore) 2013;92(2):92-7.
  27. Lopez LG, Muñoz ADR, Guarneros MP, Chavez AF, Paramo MS, Nava A, et al. Anti-Cyclic Citrullinated Peptide (Anti-CCP) and Anti-Mutated Citrullinated Vimentin (Anti-MCV) Relation with Extra-Articular Manifestations in Rheumatoid Arthritis. J Immunol Res 2014;2014:536050.
  28. Seong-KK, Bae J, Hwajeong Lee, Kim HJ, Park SH, Choe YJ. Greater prevalence of seropositivity for anti-cyclic citrullinated peptide antibody in unaffected first-degree relatives in multicase rheumatoid arthritis-affected families. Korean J Intern Med 2013;28:45-53.
  29. Hani S, Gabalawy EL, Robinson DB, Hart D, Elias B, KiemOen J. Immunogenetic Risks of Anti-Cyclical Citrullinated Peptide Antibodies in a North American Native Population with Rheumatoid Arthritis and Their First-degree Relatives. J Rheumatol 2009;36:1130-5.
  30. Goeldner I, Skare TL, Iara T, de Messias Reason, Nisihara RM, Marília BS, et al. Anti-cyclic citrullinated peptide antibodies and rheumatoid factor in rheumatoid arthritis patients and relatives from Brazil. Rheumatology 2010;49(8):1590-3.